Timeline

Voting rights breakdown

Declared beneficial owners · 12

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

• Sunstone Life Science Ventures Fund I K/S84.82%
• Auriga Ventures III84.82%
• Wellington Partners Ventures III Life Science Fund L.P84.82%
• Renaisance PME fondation suisse d investissement / Mona Lisa84.82%
• Dansk Innovationsinvestering P/S84.82%
• Aravis Venture I LP84.82%
• Novartis Bioventures Ltd84.82%
• Entrepreneurs Fund General Partners Limited84.82%
• Baltisches Haus Limited84.82%
• BioMedInvest II LP84.82%
• Symbion Capital I A/S84.82%
• Astellas Venture Capital, LLC84.82%

Notice details

Beneficial owner

Sunstone Life Science Ventures Fund I K/S

SIX listing Sunstone Life Science Ventures Fund I K/S holds 17,328,210 shares, representing 12.47% of the shares issued and is controlled by: Peter Benson, Hamngatan 17, SE 269 21 Båstad, Sweden, Sten Verland, Skovbrynet 57, 2880 Bagsværd, Denmark, Søren Lemonius, Vibeengen 38, 3460 Birkerød, Denmark, and Merete Lundbye Møller, Refshalevej 141F, 1432 Copenhagen, Denmark. Auriga Ventures III holds 12,240,710 shares, representing 8.81% of the shares issued and is controlled by: Jacques Chatain, Bernard Daugeras and Patrick Bamas, 18 Avenue Matignon 75008 Paris. Wellington Partners Ventures III Life Science Fund L.P. and Wellington Partners Ventures III Life Science Network Fund hold 11,844,070 shares, representing 8.53% of the shares issued and are controlled by: Wellington Partners Management Limited, registered at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH. Wellington Partners Management Limited is regulated by the Jersey Financial Services Commission in its capacity as general partner under the provisions of the Financial Services (Jersey) Law 1998. Renaisance PME fondation Suisse d investissement and Mona Lisa Capital AG hold 11,843,700 shares, representing 8.52% of the shares issued and are controlled by: PME fondation suisse d investissement, Parc Scientifique de l EPFL, Bâtiment PSE-C, 1015 Lausanne and Mona Lisa Capital AG, Alte Tiefenaustrasse 6, Worblaufen, Post:, 3050 Bern. Renaissance PME fondation suisse d investissement is a Swiss pension foundation. Mona Lisa Capital AG is a direct, wholly owned subsidiary of Swisscom AG. These Shares are managed by Vinci Capital (Switzerland) SA, Parc Scientifique de l EPFL, Bâtiment PSE-C, 1015 Lausanne. Any investment decision made by Renaissance PME fondation suisse d investissement with respect to its Shares is also applied to the Shares held by Mona Lisa Capital AG, pursuant to a management contract among Renaissance PME fondation suisse d investissement, Mona Lisa Capital SA and Vinci Capital (Switzerland) SA. Dansk Innovationsinvestering P/S holds 10,041,060 shares, representing 7.23% of the shares issued and is controlled by: Vaekstfonden, Strandvejen 104A, DK 2900 Hellerup and A/S Dansk Erhvervsinvestering-Vendersgade 28-1363 Copenhagen, Denmark. Aravis Venture I LP holds 9,690,670 shares, representing 6.98% of the shares issued and is controlled by: T John Diekman (Chair), Peter Anderson, Bernard Mach, Andrew Schwab and Jean-Philippe Tripet, Once Capital Place PO Box 847 GT, Grand Cayman, Cayman Islands. Novartis Bioventures Ltd. holds 8,133,710 shares, representing 5.85% of the shares issued and is controlled by: Novartis AG, Lichtstr. 35, 4056 Basel, Switzerland. Entrepreneurs Fund General Partners Limited holds 7,708,210 shares, representing 5.55% of the shares issued and is controlled by: COFRA Holding AG, Grafenauweg 10, 6300 Zug. Baltisches Haus Limited holds 5,414,210 shares, representing 3.90% of the shares issued and is controlled by: Mr. George Ortiz, Brussels, Belgium, Mr. Oliver Ortiz, Vilnius, Lithuania and Mr. Nicolas Ortiz, Vilnius, Lithuania. BioMedInvest II LP holds 5,256,220 shares, representing 3.78% of the shares issued and is controlled by: Dr. Markus Hosang, Mr. Thomas Moeller, Dr. Gerhard Ries, Mr. Kevin Gilligan and Mr. Derek Baudains Provident House, Haviland Street, St. Peter Port, Guernsey. Symbion Capital I A/S holds 5,023,490 shares, representing 3.62% of the shares issued and is controlled by: Mrs. Ulla Brockenbuus-Schack, 4100 Ringsted, Denmark, via UBS 2 ApS; Mr. Lars Andersen, 2840 Holte, Denmark, via GM Invest ApS; Mr. Peter Tottrup, 2700 Bronshoj, Denmark, via Tottrup SCD ApS; Mr. Carsten Schou, 2840 Holte, Denmark, via Papilio Aps. Astellas Venture Capital, LLC holds 4,876,970 shares, representing 3.51% of the shares issued and is controlled by Astellas Pharma Inc., 2-3-11, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan. Further information is available under: http://www.evolva.com/investors/shareholder-information